Additional malignancies shorten overall survival in chronic lymphocytic leukemia irrespective of chromosomal aberrations: A retrospective cohort study.
Medicine (Baltimore)
; 102(6): e32906, 2023 Feb 10.
Article
in English
| MEDLINE | ID: covidwho-2258349
ABSTRACT
The aim of this study was to determine the incidence of other malignancies (OMs) in patients with chronic lymphocytic leukemia (CLL) and to identify parameters associated with the occurrence of OMs in addition to CLL. This retrospective cohort study was conducted by examining the records of CLL patients who applied to a tertiary hospital between January 2013 and December 2021. The cases were divided into 2 groups, CLL (nâ
=â
107) and CLLâ
+â
OM (nâ
=â
25), according to the presence of additional malignancy. Lymphocyte count (Pâ
=â
.014), white blood cell count (Pâ
=â
.006), and hemoglobin (Pâ
=â
.034) were significantly higher in the CLL group. Rai stage IV percentage (Pâ
=â
.015), Binet stage B percentage (Pâ
=â
.043), progression, and sepsis percentages (Pâ
=â
.008) were significantly higher in the CLLâ
+â
OM group. Overall survival time was significantly lower in the CLLâ
+â
OM group (Pâ
=â
.032). Most OMs had been diagnosed before CLL (63.64%) in the no-treatment group, while the majority of OMs were diagnosed after CLL (78.57%) in the treatment group (Pâ
=â
.032). CLL patients with OM had a more advanced CLL stage, and survival was significantly shorter in these patients. In addition, CLL-associated OM appears to occur more frequently in the post-treatment period.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Leukemia, Lymphocytic, Chronic, B-Cell
Type of study:
Cohort study
/
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Medicine (Baltimore)
Year:
2023
Document Type:
Article
Affiliation country:
MD.0000000000032906
Similar
MEDLINE
...
LILACS
LIS